This list of clinical research protocols relating to melanoma is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at http://cancernet.nci.nih.gov/trialsrch.shtml. A searchable Web site developed by the National Library of Medicine is also available at http://clinicaltrials.gov.

SELECTED CLINICAL RESEARCH PROTOCOLS FOR MELANOMA

Phase II

**MSKCC-99004, NCI-G99-1619**
Phase II Pilot Study of Fluodeoxyglucose F 18 Positron Emission Tomography and CT Imaging in Preoperative Evaluation of Patients With Stage III or IV Melanoma

**E-1696**
Phase II Randomized Study of Immunization With an HLA-A2 Multiepitope Peptide Vaccine Comprised of MART-1:27-35, gp100:209-217 (210M), and Tyrosinase:368-376 (370D) Peptides Alone or in Combination With Sargramostim (GM-CSF) and/or Interferon alfa-2b in HLA-A2 Positive Patients With Metastatic Melanoma

**CWG-UIC-T98-0027, NCI-T98-0027**
Phase II Randomized Study of Mutated gp100 Melanoma Peptide With High Dose Interleukin-2 in HLA-A2.1 Positive Patients With Metastatic Melanoma
Chairperson: Jeffrey A. Sosman. Telephone: 312-996-1588. Lead organization: University of Illinois at Chicago Health Sciences Center. Age range: 16 and over.

**SWOG-9430**
Phase II Study of Complete Surgical Resection in Patients With Stage IV Melanoma

**NCI-01-C-0193, NCI-5369**
Phase II Randomized Study of Tyrosinase-Related Protein-2:180-188 Peptide Vaccine With or Without Interleukin-2 in Patients With HLA-A0201-Positive Refractory Metastatic Melanoma

**DUMC-1340-99-7, NCI-G99-1617**
Phase II Study of Allogeneic Mixed Chimerism Peripheral Blood Stem Cell Transplantation Utilizing In Vivo and In Vitro Monoclonal Antibody CD52 (Campath-1H) in Patients With High Risk Hematologic Malignancies or Diseases

**NCI-98-C-0095, NCI-T98-0012**
Phase II Study of Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide Alone or in Conjunction With Interleukin-2 in Patients With Metastatic Melanoma Who Have Failed Prior Vaccine Therapy

**NCI-98-C-0086**
Phase II Study of DNA Encoding the gp100 Anti-
gen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma

**CLB-509901** Phase II Study of gp100 Human Melanoma Peptide Vaccine and Interleukin-2 in Patients With Advanced Melanoma

**MDA-ID-01284, NCI-5345** Phase II Study of Imatinib Mesylate (STI571) in Patients With Metastatic Melanoma

**SWOG-S0026** Phase II Study of Interferon alfa and Thalidomide in Patients With Stage IV Melanoma

**MSKCC-99047, NCI-G99-1664** Phase II Study of Isolated Limb Infusion With Melphanal and Dactinomycin in Patients With Primary or Recurrent, Unresectable Regional Melanoma or Soft Tissue Sarcoma of the Extremity

**FHCRC-1462.00, NCI-G00-1841** Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation With Fludarabine and Total Body Irradiation, Followed By Cyclosporine and Mycophenolate Mofetil, Followed By Donor Lymphocyte Infusion in Patients With Stage IV Melanoma

**UCCRC-10325, NCI-T99-0111, CWRU-1699** Phase II Study of O6-Benzylguanine and Carmustine in Patients With Unresectable Locally Recurrent or Metastatic Melanoma

**JHOC-98111005, NCI-T96-0116, JHOC-JH9875, JHOC-T96-0116** Phase II Study of Pyrazoloacridine in Patients With Metastatic Cutaneous or Ocular Melanoma

**MSKCC-01005, NCI-G01-2031** Phase II Study of Temozolomide and Pegylated Interferon alfa in Patients With Advanced Melanoma

**UTHSC-IDD-99-27, NCI-66, SACI-IDD-99-27** Phase II Study of Thalidomide and SU5416 in Patients With Metastatic Melanoma
Chairperson: Eric Keith Rowinsky. Telephone: 210-616-5945. Lead organization: University of Texas Health Science Center at San Antonio. Age range: 18 and over.

**Phase III**

**E-1697** Phase III Randomized Adjuvant Study of High Dose Interferon Alfa-2b Therapy in Patients With Stage II and III Melanoma

**MDA-ID-95196, NCI-G96-1089, MDA-DM-95196** Phase III Randomized Adjuvant Study of Interferon Alfa-2b Alone vs Biochemotherapy Using Cisplatin, Vinblastine, Dacarbazine (DTIC), IFN-A, and Interleukin-2 (IL-2) in Melanoma Patients With Regional Lymph Node Metastases
Chairperson: Agop Y. Bedikian. Telephone: 713-792-2921. Lead organization: University of Texas - MD Anderson Cancer Center. Age range: 10 to 70.

**JWCI-MC-3-001A, NCI-V99-1576, CV-MMAIT-3-001** Phase III Randomized Study of BCG Plus a
Polyvalent Melanoma Vaccine (CancerVax) Versus BCG Plus Placebo in Patients With Resected Stage III Melanoma

GENTA-GM301 Phase III Randomized Study of Dacarbazine With or Without Augmerosen in Patients With Advanced Malignant Melanoma

NCI-T98-0085, NCI-99-C-0051B Phase III Randomized Study of High Dose Interleukin-2 With or Without gp100 Antigen in Patients With Metastatic Cutaneous Melanoma

ACOSOG-Z0020 Phase III Randomized Study of Hyperthermic Isolated Limb Perfusion and Melphalan With or Without Tumor Necrosis Factor in Patients With Localized, Advanced, Extremity Melanoma


SWOG-S0008 Phase III Randomized Study of Interferon alfa Versus Cisplatin, Vinblastine, and Dacarbazine Plus Interferon alfa and Interleukin-2 in Patients With High-Risk Melanoma

SWOG-S0008 Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprised of Tyrosinase:368-376, gp100:209-217 Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma


E-E3695 Phase III Study of Cisplatin, Vinblastine, and Dacarbazine With or Without Interleukin-2 and Interferon alfa-2b in Patients With Metastatic Malignant Melanoma